




BALKAN VALVES


13th - 14th MARCH 2026

EUROPEAN INTERBALKAN MEDICAL CENTER
THESSALONIKI / GREECE



more info

Event Endorsed by:



PCO: INVENTICS A.E. / Medevents.gr

T. 2310 474 400 / E. info@medevents.gr / W. www.medevents.gr

GNT0 License: 0933E60000074600

BALKAN VALVES 2026

Directors:

Professor Luigi P. Badano, FESC, FACC, Honorary Fellow ASE, BSE, and EACVI

Dr Mani Vannan, MBBS, FACC, FAHA

Dr Stefanos Karagiannis, FESC, FEACVI

Dr Konstantinos Papadopoulos, FESC, FEACVI

Thessaloniki 13th – 14th of March 2026

Congress venue: Interbalkan Medical Center, Thessaloniki

PCO: Inventics

Hybrid form (physical presence and online participation) through online platform and live-streaming

Scientific committee:

1. **BOGDAN POPESCU**
2. **ATTILA KOVACS**
3. **JADRANKA SEPAROVIC**
4. **VLISSIOS NINIOS**
5. **KRASIMIRA HRISTOVA**
6. **IVAN STANKOVIC**
7. **ELIZABETA SRBINOVSKA KOSTOVSKA**
8. **BLAZEJ MICHALSKI**

PROGRAM

Friday 13 March 2026

09:00-10:30 **Session 1: Hands-on training workshop I (pg.14)**
Live scanning on echo machines and off-line analysis on workstations in 5 parallel rooms

10:30-10:45 *Coffee break*

10:45-12:45 **Session 2: Focus on aortic valve**
Chairpersons: V. Kamperidis, A. D. Mavrogianni
Discussants: A. Taleb, A. Roumpelakis, I. Karabinos, A. Tzikas

Case A patient with a challenging aortic valve disease: case presentation
V. Reskovic Luksic

Theory Severe asymptomatic aortic stenosis: is watchful waiting still a wise option?
E. Srbinovska Kostovska

Theory Prognosis and management of moderate aortic stenosis. Is myocardial damage important?
G. Georgiou

Theory Risk stratification in patients with severe aortic regurgitation
K. Hristova

Theory Myocardial-hemodynamic coupling in aortic regurgitation grading
J. Separovic Hanzevacki

Theory TAVR or SAVR in high-risk patients with aortic regurgitation?
E. Agricola

Case A patient with a challenging aortic valve disease: heart team discussion

PROGRAM

Friday 13 March 2026

12:45-13:15

Opening Ceremony

G. Zerdilas / Chief Managing Director of Athens Medical Group

N. Mpatzios / General Secretary of Medical Association of Thessaloniki

A.- D. Mavrogianni / Member of the Board of the Hellenic Society of Cardiology

G. Bompotis / Member of the Board of the Cardiological Society of Northern Greece

L. Badano / Congress Director

M. Vannan / Congress Director

S. Karagiannis / Congress Director

K. Papadopoulos / Congress Director

13:15-14:00

Lunch break

14:00-16:00

Session 4: Focus on tricuspid valve

Chairpersons: L. Badano, P. Nihoyannopoulos

Discussants: M. Tomaselli, K. Katogiannis, N. Kadoglou, S. Mihaila-Baldea

Case

A patient with a challenging secondary tricuspid regurgitation: case presentation
I.Ninios

Theory

Is it time to revise the guidelines about the echocardiographic assessment of tricuspid regurgitation?

L. Badano

Theory

Phenotyping vs Classification vs scores for tricuspid valve disease

M. Vannan

PROGRAM

Friday 13 March 2026

Theory

How artificial intelligence can help to standardize the assessment of right ventricular dysfunction and tricuspid regurgitation severity

A. Kovacs

Theory

How to assess RV function in patients with tricuspid regurgitation

S. Mihaila- Baldea

Theory

Tricuspid-TEER vs TTVR: 2026 update

E. Donal

Case

A patient with a challenging secondary tricuspid regurgitation: heart team discussion

Discussion

16:00-17:00

Dissecting 2025 ESC Guidelines on Heart Valve Diseases

Panelists: **A. Stefanidis, E. Donal**

2025 ESC / EACTS Recommendations on the Management of Aortic Valve Disease

B. Cosyns

2025 ESC / EACTS Recommendations on the Management of Mitral Valve Disease

A. Papachristidis

2025 ESC / EACTS Recommendations on the Management of Tricuspid Valve Disease

L. Badano

17:00-17:30

Coffee break

17:30-18:00

Satellite Lecture (pg.18)

18:00-19:00

Session 5: Hands-on training workshop II (pg.15)

In 5 parallel rooms

PROGRAM

Saturday 14 March 2026

09:00-10:30 **Session 6: Hands-on training workshop III (pg.16)**

In 5 parallel rooms

10:30-10:45

Coffee break

10:45-12:45

Session 7: Focus on mitral valve

Chairpersons: K. Papadopoulos, P. Lancellotti

Discussants: O.Ozden Kayhan, K. Kipourou, A. Theodosis – Georgilas, S. Mihaila-Baldea

Case

A patient with a challenging mitral regurgitation: case presentation
I. Kotlar

Theory

Three-dimensional echocardiography for anatomy and severity assessment of mitral Regurgitation
C. Fiore

Theory

Risk stratification in patients with mitral regurgitation
K. Spargias

Theory

Selection criteria and echocardiographic guidance of mitral-TEER
K. Papadopoulos

Theory

Atrial and ventricular secondary mitral regurgitation treatment: Current evidence.
E. Sade

Theory

Mitral-TEER vs TMVR: 2026 update
F. Maisano

Case

A patient with a challenging mitral regurgitation: heart team discussion

Discussion

PROGRAM

Saturday 14 March 2026

12:45-13:15

Lunch break

13:15-14:15

Session 8: PCR Session

Beyond the 2025 ESC/EACTS Valvular Heart Disease Guidelines

Chairpersons: **M. Gilard, L. Badano**

Discussants: **R. Parma, N. Ajmone Marsan, T. Zaglavara, K. Papadopoulos, A. Kolyda**

Welcome and session objectives

M. Gilard

Part 1 | Aortic Senosis – Rethinking the Younger Patient

Case presentation – How should I treat?

A younger patient with severe AS, low surgical risk, and borderline symptoms

POLL “Would you intervene now or continue surveillance?”

R.Parma

Multimodality imaging: the CT-first revolution

- *CCTA for coronary assessment – replacing the cath lab when pre-test CAD probability $\leq 50\%$*

- *Comprehensive CT TAVI planning: annulus, calcium, coronary heights, LVOT, access*

- *CMR for myocardial fibrosis in borderline and asymptomatic cases*

- *When to escalate to invasive coronary angiography*

T. Zaglavara

Imaging-driven decision-making

Discussion and audience interaction | POLL “TAVI, SAVR, or continued surveillance?”

Open discussion and audience Q&A | *Discussion and audience interaction*

Case resolution – How did I treat?

Outcome reveal and guideline alignment check

R.Parma

PROGRAM

Saturday 14 March 2026

Part 2 | Secondary MR – From GDMT to Transcatheter Intervention

Case presentation – How should I treat?

A patient with cardiomyopathy, reduced LVEF, severe secondary MR, persistent symptoms despite optimised GDMT

POLL “Is this patient’s GDMT truly optimised?”

K. Papadopoulos

Imaging for patient selection in secondary MR

- *Ventricular vs. atrial SMR phenotypes: imaging differentiation and clinical implications*
- *Echocardiographic criteria for disproportionate MR – the COAPT proportionality framework*
- *3D TEE assessment of MV anatomy for TEER feasibility*
- *CMR: viability, scar burden, and RV function*

N. Ajmone Marsan

Who benefits most from transcatheter intervention? | Discussion and audience interaction

Percutaneous management of secondary MR

- *TEER technique: device selection, grasping strategy, residual MR targets*
- *When TEER is not enough: the emerging role of TMVR*
- *Timing of intervention: early referral vs. the “too sick, too late” paradigm*
- *Combined valve interventions: addressing concomitant tricuspid regurgitation*

K. Papadopoulos

Open discussion and audience Q&A | *Discussion and audience interaction*

Case resolution – How did I treat?

Outcome reveal and guideline alignment check

K. Papadopoulos

Take-home messages

L. Badano

PROGRAM

Saturday 14 March 2026

14:15-16:15

Session 9: Post-procedural assessment of valvular interventions

Chairpersons: S. Karagiannis, V. Ninios

Discussants: D. Ketikoglou, P. Papadimitriou, D. Tsiapras, K. Aggeli

Theory

Complications of endoscopic mitral valve repair

A. Pitsis

Theory

Evaluation and treatment of paravalvular leaks

H. Mahmoud - Elsayed

Theory

TAVI bioprosthesis degeneration. Is TAVI-in-TAVI the next best option?

K. Toutouzas

Theory

Diagnosis and management of prosthetic valve endocarditis

B. Popescu

Theory

Mitral-TEER complications

M. Chrissoheris

Theory

How to manage residual mitral regurgitation after TEER?

P. Lancellotti

Discussion

16:15-16:30

Coffee break

16:30-17:00

Satellite Lecture (pg.18)

PROGRAM

Saturday 14 March 2026

17:00-18:00 **Session 10: Hands-on training workshop IV (pg.17)**
In 5 parallel rooms

18:00-19:00 **Echo @ jeopardy**
Moderators: S. Karagiannis, K. Papadopoulos, L. Badano, M. Vannan

The "Greek" Team
V. Sachpekidis, T. Zaglavara, A. Stefanidis, C. Papadopoulos

The "European" Team
E. Agricola, P. Lancellotti, K. Kipourou, C. Fiore

The "Balkan" Team
V. Reskovic Luksic, I. Kotlar, S. Mihaila-Baldea, B. Popescu

FACULTY LIST

- K. Aggeli** / Professor of Cardiology, 1st University Cardiology Department, "Hippokration" General Hospital, Athens
- E. Agricola** / Professor of Cardiology, San Raffaele Hospital, IRCCS, Milan, Italy Vita-Salute University, Milan, Italy
- N. Ajmone Marsan** / Consultant Cardiologist, Department of Cardiology, Leiden University Medical Center, the Netherlands
- L. Badano** / MD, PhD, FESC, FACC Honorary Fellow ASE, BSE and EACVI, Professor of Cardiovascular Medicine, University of Milano-Bicocca, Director of the Integrated Cardiovascular Diagnosis Unit, Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Milan, Italy
- A. Badescu** / Cardiologist, Faculty of Medicine, Ovidius University of Constanta, Constanta, Romania
- M. Chrissoheris** / Cardiologist, Associate Director, Transcatheter Heart Valves Department, HYGEIA Hospital, Athens, Greece
- B. Cosyns** / Head of Cardiology Dept, Co-director of in vivo and cellular imaging center (ICMI), Co-director of the CHVZ core lab in coronary artery physiology, Professor of Clinical Cardiology, University of Brussels, Belgium
- E. Donal** / Professor of Cardiology, Chu Rennes - Universite Rennes1-LTSl-Inserm 1099
- S. Evangelou** / Cardiologist, MD, FSCCT, European Interbalkan Medical Center, Thessaloniki, cardiac CT specialist (SCCT Level 3), member of the Education committee and of the International Task Force of SCCT
- C. Fiore** / Corrado Fiore MD, FASE, FEACVI, Cardiologist, Head of Cardiology Department and EchoLab Città di Lecce Hospital GVM, Lecce, Italy
- G. Georgiou** / Interventional Cardiologist, Director, Hemodynamic Laboratories, Cardiology Department, Apollonio Private Hospital, Nicosia, Cyprus
- P. Giannakopoulou** / Cardiologist, Consultant of Cardiology Dept, "G. Papanikolaou" GH, Thessaloniki, Greece
- M. Gilard** / Interventional cardiologist / Cardiologist, Faculty of Medicine and Health Sciences - Brest, France
- T. Gossios** / Assistant Professor in Cardiology, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki
- L. Herbots** / Cardiologist, Jessa Hospital Hasselt, Belgium

FACULTY LIST

K. Hristova / MD, PhD, FESC, FEACVI, Associate Professor of Cardiology, Sofia University, Faculty of medicine, Center for cardiovascular Diseases, Sofia, Bulgaria

I. Ikonmidis / Professor of Cardiology, 2nd Cardiology Clinic of National and Kapodistrian University of Athens, Medical School, General University Hospital "Attikon", Athens, Greece

N. Kadoglou / Assistant Professor of Cardiology, University of Cyprus

D. Kaipis / Cardiologist, European Interbalkan Medical Center, Thessaloniki, Greece

V. Kamperidis / Assistant Professor of Cardiology and Cardiac Imaging AUTH, 1st Cardiology Dept, AHEPA University General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

I. Karabinos / MD, MSc, PhD, Cardiologist, Director, 2nd Cardiology Dept, Euroclinic, Athens

S. Karagiannis / MD, PhD, FESC, Cardiologist, Head of Echocardiology Dept, Athens Medical Center, Athens

K. Katogiannis / MD, PhD, FESC, FEACVI, Cardiologist, Laboratory of Preventive Cardiology and Laboratory of Echocardiography, 2nd Cardiology Department, National and Kapodistrian University of Athens, General Hospital Attikon, Athens

D. Ketikoglou / MD, PhD, FEACVI, FESC, Cardiologist, Head of Echocardiography laboratory, 1st Cardiology Clinic, European Interbalkan Medical Center, Thessaloniki, Greece

K. Kipourou / Consultant Cardiologist, University Hospital Dorset, Bournemouth Hospital, UK

A. Kolyda / MSc, Cath Lab Radiographer at General Hospital Asklepieio, Voulas, co-chair of EAPCI NAPs committee, ISRRRT Regional coordinator of education-EUROPE

I. Kotlar / MD, Cardiologist, University Clinic of Cardiology, Skopje, North Macedonia

A. Kovacs / Professor of Cardiology, Heart and Vascular Center, Semmelweis University, Budapest, Hungary

P. Lancellotti / Professor of Cardiology University of Liège CHU Sart Tilman, Liège, Belgium

S. Loizos / Consultant Cardiologist, HYGEIA Hospital, Athens

H. Mahmoud-Elsayed / MD, FESC, FASE, FEACVI. Consultant Cardiologist, Director of Echocardiography Lab, Aswan Heart Center, Magdi Yacoub Foundation, Aswan, Egypt, Director of Cardiac Investigation Center (CIC) Cairo, Egypt

F. Maisano / Professor in Cardiovascular Surgery, Director of Valve Center, San Raffaele Hospital, Milan, Italy

FACULTY LIST

- A. D. Mavrogianni** / Interventional Cardiologist, Director, Head of Catheterization Laboratory, Cardiology Dept, "G. Papanikolaou" GH, Thessaloniki, Greece
- B. Michalski** / Cardiologist, Medical University of Lodz, Lodz (Poland)
- S. Mihaila-Baldea** / Senior Lecturer in Cardiology, MD, PhD, EACVI Scientific Documents Committee member, Member of the Board of Romanian Society of Cardiology, Dept of Cardiology and Cardiovascular Surgery, The Emergency and University Hospital Bucharest, The University of Medicine and Pharmacy Carol Davila Bucharest Romania
- K. Mitrousi** / MD, Cardiologist, Interbalkan Medical Center, Thessaloniki, Ygeia Ptolemaida, Greece, Honorary Consultant Cardiologist, Cardiac MRI unit, Bristol Heart Institute
- P. Nihoyannopoulos** / MD, FRCP, FACC, FESC, FACC, FAHA, Professor of Cardiology, Imperial College London, NHLI, Hammersmith Hospital, London, UK, Emeritus Professor of Cardiology, National and Kapodistrian University of Athens, Greece
- I. Ninios** / Interventional Cardiologist, Doctor of Cardiology of A.U.Th, European Interbalkan Medical Center, Thessaloniki, Greece
- V. Ninios** / Interventional Cardiologist, Director of Cardiology Department, European Interbalkan Medical Center, Thessaloniki
- Ö. Özden Kayhan** / Cardiologist, ESC Education Committee Member, HIT Board Member, Memorial Bahcelievler Hospital, Head of Cardiovascular Imaging Dept, Istanbul, Turkey
- E. Pagourelis** / MD, MSc, PhD, FESC, FEACVI, Assistant Professor in Cardiology-Echocardiography, Third Cardiology Department, Hippokrateion General Hospital, Aristotle University of Thessaloniki, Greece
- A. Papachristidis** / MD, PhD, MRCP, FESC, Consultant Cardiologist and Adjunct Senior Lecturer, King's College Hospital NHS Foundation Trust and King's College London, UK
- I. Palios** / Cardiologist, Director Cardiac MRI Dept., Metropolitan Hospital, Athens, Greece
- P. Papadimitriou** / Consultant Cardiologist, Echocardiology Department, Athens Medical Center, Greece

FACULTY LIST

- C. Papadopoulos** / Clinical Director, 2nd Cardiology Dept, Korgialenio - Benakio (Red Cross) GH, Athens
- K. Papadopoulos** / MD, PhD, FESC, FEACVI, Cardiologist, Head of Echocardiography Lab, 3rd cardiology Clinic, European Interbalkan Medical Center, Thessaloniki
- R. Parma** / Department of Cardiology and Structural Heart Diseases, GCM, Medical University of Silesia, Ziolowa 47, 40-635 Katowice, Poland
- A. Pitsis** / MD, PhD, FETCS, FESC, Cardiac Surgeon, Director of the 1st Department of Cardiac Surgery, European Interbalkan Medical Center, Thessaloniki, Greece
- B. Popescu** / MD, PhD, FESC, FACC, HonFEACVI, Professor of Cardiology, University of Medicine and Pharmacy "Carol Davila", Head, Cardiology Department, Emergency Institute of Cardiovascular Diseases "Prof. Dr. C. C. Iliescu", Bucharest, Romania, Past-President, European Association of Cardiovascular Imaging, Past-President, Romanian Society of Cardiology, Editor-in-Chief, Romanian Journal of Cardiology
- V. Reskovic Luksic** / Cardiologist, Department for Cardiovascular Diseases, University Hospital Centre Zagreb, Croatia
- A. Roubelakis** / MD, PhD, FETCS, Cardiac Surgeon, Director of 3rd Department of Cardiac Surgery, Athens Medical Center
- V. Sachpekidis** / Consultant Cardiologist, "Papageorgiou" GH, Thessaloniki, Greece
- L. Sade** / Professor of Medicine, University of Pittsburgh & University of Pittsburgh Medical Center (UPMC), Heart & Vascular Institute, Department of Cardiology, Pittsburgh, PA, USA
- J. Separovic Hanzevacki** / Professor of Cardiology, Valvular Heart Disease Dpt, Head, Department of Echocardiography and Heart Hemodynamics, Head Department of Cardiovascular Diseases Clinical Hospital Centre Zagreb, Working Group on Echocardiography of the Croatian Cardiac Society, Chair
- A. Siskos** / Interventional cardiologist, PhD(c) Interbalkan Hospital Thessaloniki, Thoraxcenter-Erasmus U.M.C.
- K. Spargias** / MD, PhD, FESC, Interventional Cardiologist, Director, Transcatheter Heart Valves Department, HYGEIA Hospital, Athens
- E. Srbinovska Kostovska** / Professor of Cardiology, University Clinic of Cardiology, Medical faculty, University "St Cyril and Methodius", Skopje, North Macedonia
- A. Stefanidis** / Consultant Cardiologist, Gen. Host. of Nikea, Athens, Greece, EACVI lab accreditation committee (Chair)

FACULTY LIST

A. Taleb / Interventional Cardiologist, Athens Medical Center

A. Theodosis - Georgilas / Consultant Cardiologist, "Tzaneio" General Hospital of Piraeus

M. Tomaselli / Cardiologist, Department of Cardiology, Istituto Auxologico italiano, San Luca Hospital, Milan Italy

K. Toutouzas / Professor of Cardiology, Athens University, 1st University Cardiology Department, Hippokration General Hospital, Athens, Greece, Director of Structural Heart Disease and Valve Disease Unit, HCS President

D. Tsiapras / Consultant Cardiologist, Non-Invasive Cardiology Specialist, Cardiology Department, Onassis Hospital, Athens

A. Tzikas / MD, PhD, FESC, Interventional Cardiologist, Structural & Congenital Heart Disease, Hippokratio University Hospital of Thessaloniki & European Interbalkan Medical Center, Thessaloniki, Greece

M. Vannan / MBBS, FACC, FAHA, FASE, Cardiologist, Structural and Valvular Center of Excellence, Marcus Heart Valve Center, Piedmont Heart Institute, Atlanta, GA, USA

D. Vasile / Cardiologist, Emergency University Hospital of Bucharest

T. Zaglavara / MD, PhD, Cardiologist, Advanced Cardiovascular Imaging Department and 1st Cardiothoracic Surgery Department, European Interbalkan Medical Center, Thessaloniki, Greece

WORKSHOPS | Friday 13 March 2026

09:00-10:30

Session 1: Hands-on training workshop I

Room 1: Chambers assessment part I > Advanced Evaluation of Left Ventricle with 4D, strain and Myocardial Work [**GE Healthcare workshops**]

(**K. Papadopoulos/L. Badano/B. Popescu/ A. Badescu**)

Room 2: Station #1: TOE scanning with Vivid Pioneer and 6VT-D probe | Station #2: Exercise echocardiography with eBike and Vivid E95 [**GE Healthcare workshops**]

(**S. Karagiannis/ C. Papadopoulos**)

Room 3: Scanning and hands-on training on MitraClip simulator for trans-septal puncture, manipulation of the guide-catheter and grasping of mitral valve [**Abbott MitraClip workshops**]

Moderator: B. Michalski

Room 4: Clinical case corner > Cardiac Amyloidosis

Panelists: K. Hristova, P. Giannakopoulou

Diagnostic algorithm for cardiac amyloidosis assessment (**I. Ikonomidis**)

Cardiac amyloidosis and valvulopathies (**T. Gossios**)

Cardiac amyloidosis case #1 (**V. Sachpekidis**)

Cardiac amyloidosis case #2 (**A. Badescu**)

Cardiac amyloidosis case #3 (**E. Pagourelis**)

Room 5: 4D Assessment of Mitral Valve [**Philips-TomTec workshops**]

Instructors: H. Mahmoud-Elsayed, V. Sachpekidis

WORKSHOPS | Friday 13 March 2026

18:00-19:00

Session 5: Hands-on training workshop II

Room 1: Chambers assessment part II > Advanced Evaluation of Right Ventricle with 4D and strain imaging [**GE Healthcare Workshops**]

(**L. Badano/ M. Tomaselli**)

Room 2: Station #1: TOE scanning with Vivid Pioneer and 6VT-D probe | Station #2: Exercise echocardiography with eBike and Vivid E95 [**GE Healthcare workshops**]

(**K. Papadopoulos/ S. Karagiannis/ A. Badescu**)

Room 3: Scanning and hands-on training on MitraClip simulator for trans-septal puncture, manipulation of the guide-catheter and grasping of mitral valve [**Abbott MitraClip workshops**]

Moderator: **K. Kipourou**

Room 4: Clinical case corner > Mastering TEER procedures

Panelists: **I. Ikonmidis, B. Michalski**

When should I use MitraClip and when PASCAL device? (**K. Spargias**)

TEER in secondary Ventricular MR (**M. Chrissoheris**)

Combined mitral and tricuspid TEER (**I. Ninios**)

TEER in complex degenerative MV disease (**A. Papachristidis**)

CPET echo for decision making for mitral TEER (**L. Herbots**)

Room 5: Chambers assessment part II >Advanced Evaluation of Right Ventricle with 4D and strain imaging [**Philips-TomTec workshops**]

Instructors: **H. Mahmoud-Elsayed, V. Sachpekidis**

WORKSHOPS | Saturday 14 March 2026

09:00-10:30

Session 6: Hands-on training workshop III

Room 1: 4D Valves Assessment > MV | TV Assessment [GE Healthcare workshops]
MV Assesment (**K. Papadopoulos/C. Fiore**)
TV Assesment (**L. Badano/ M. Tomaselli**)

Room 2: Station #1: TOE scanning with Vivid Pioneer and 6VT-D probe |
Station #2: Exercise echocardiography with eBike and Vivid E95 [GE Healthcare
workshops]
(**C. Papadopoulos/ I. Ikonmidis**)

Room 3: Scanning and hands-on training on MitraClip simulator for trans-septal
puncture, manipulation of the guide-catheter and grasping of mitral valve [Abbott
MitraClip workshops]
Moderator: M. Chrissoheris

Room 4: Clinical case corner > Mastering Aortic Valve
Panelists: E. Agricola, D. Kaipis, S. Evangelou, J. Separovic Hanzevacki

2D/3D assessment of aortic stenosis (**A. Stefanidis**)
Stress Echocardiography in Aortic Stenosis Evaluation (**S. Karagiannis**)
How to use CT for TAVI assessment (**K. Mitrousi**)
Cardiac MRI in aortic regurgitation (**S. Loizos**)
A challenging TAVI case #1 (**A. D. Mavrogianni**)
A challenging TAVI case #2 (**A. Siskos**)
A challenging TAVI case #3 (**D.Vasile/S. Mihaila-Baldea**)

Room 5: 4D Assessment of Tricuspid and Aortic Valve [Philips-TomTec workshops]
Instructors: H. Mahmoud-Elsayed, V. Sachpekidis

WORKSHOPS | Saturday 14 March 2026

17:00-18:00

Session 10: Hands-on training workshop IV

Room 1: Stress Echocardiography > In ischemia detection | In Valvulopathies [GE Healthcare workshops]

(S. Karagiannis/ C. Papadopoulos)

Room 2: Station #1: TOE scanning with Vivid Pioneer and 6VT-D probe | Station #2: Exercise echocardiography with eBike and Vivid E95 [GE Healthcare workshops]

(B. Popescu/ I. Ikonomidis)

Room 3: Scanning and hands-on training on MitraClip simulator for trans-septal puncture, manipulation of the guide-catheter and grasping of mitral valve [Abbott MitraClip workshops]

Moderator: I. Ninios

Room 4: Clinical case corner > Clinical examples of how to evaluate and treat HOCM patients

Speakers: K. Papadopoulos, E. Pagourelas, I. Palios

Panelists: P. Giannakopoulou, I. Palios

Room 5: Chambers assessment part I >Advanced Evaluation of Left Ventricle [Philips-TomTec workshops]

Instructors: H. Mahmoud-Elsayed, V. Sachpekidis

SATELLITE LECTURES

Friday 13 March 2026

17.30-18.00 Satellite Lecture Sponsored by Meril
Panelists: **I. Ikonmidis, B. Michalski**

From Data to Practice: The Latest Clinical Evidence on Myval
Expanding Horizons: Practical Insights into Myval Aortic TAVR and Beyond
V. Ninios

Saturday 14 March 2026

16.30 -17.00 Satellite Lecture Sponsored by Bristol Myers Squibb
Panelists: **P. Giannakopoulou, I. Palios**

Therapeutic Role of Selective Cardiac Myosin Inhibitors in Symptomatic Obstructive
Hypertrophic Cardiomyopathy
K. Papadopoulos

BALKAN VALVES

13th - 14th MARCH 2026

EUROPEAN INTERBALKAN MEDICAL CENTER

THESSALONIKI / GREECE



ACKNOWLEDGEMENTS

GOLD SPONSOR



SILVER SPONSOR



BRONZE SPONSOR

Meril

BALKAN VALVES

13th - 14th MARCH 2026

EUROPEAN INTERBALKAN MEDICAL CENTER

THESSALONIKI / GREECE



ACKNOWLEDGEMENTS

SPONSORS



Menarini Hellas



Pharmaceutical Laboratories S.A.



Edwards™





Abbott

CONTROL MEETS EFFICIENCY

MitraClip™

Transcatheter Edge-to-Edge Repair

TriClip™

Transcatheter Edge-to-Edge Repair

G5 THE NEXT GENERATION OF TRANSCATHETER EDGE-TO-EDGE REPAIR SYSTEMS

CAUTION: Product(s) intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at <https://www.eifu.abbott/> for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Information contained herein for DISTRIBUTION in Greece and Cyprus ONLY. Always check the regulatory status of the device in your region. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

MitraClip™ G5 System and TriClip™ G5 System. CE marked medical devices. CE 2797.
Legal manufacturer: Abbott Medical, 177 County Road B East, St. Paul, Minnesota 55117, USA.

ABBOTT MEDICAL HELLAS LTD, Iroos Matsi & Archaeou Theatrou 17456, Alimos

™ Indicates a trademark of the Abbott group of companies. www.my-connect.com
©2025 Abbott. All rights reserved. 9-GR-2-16736-01 10-2025

CAMZYOS®
(mavacamten)^{2.5, 5, 10, 15mg}
capsules

Ο πρώτος εγκεκριμένος αναστολέας της καρδιακής μυσίνης για την αποφρακτική υπερτροφική μυοκαρδιοπάθεια (κατηγορίας II-III κατά την Καρδιολογική Εταιρεία της Νέας Υόρκης, ΝΥΗΑ)^{1,2}

2x

περισσότεροι ασθενείς βελτίωσαν την κατηγοριοποίηση κατά ΝΥΗΑ κατά ≥1 κατηγορία έναντι του εικονικού φαρμάκου

>20x

μείωση στη μέση κλίση στον LVOT μετά από άσκηση έναντι του εικονικού φαρμάκου



ΘΕΡΑΠΕΙΑ ΑΠΟ ΤΟΥ ΣΤΟΜΑΤΟΣ
Με εξατομικευμένη δοσολογία για βέλτιστες εκβάσεις

Το CAMZYOS® ενδείκνυται για τη θεραπεία της συμπτωματικής (κατηγορίας II-III κατά την Καρδιολογική Εταιρεία της Νέας Υόρκης, ΝΥΗΑ) αποφρακτικής υπερτροφικής μυοκαρδιοπάθειας¹

ΝΥΗΑ = Καρδιολογική Εταιρεία της Νέας Υόρκης.

Πριν την συνταγογράφηση συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος, που διατίθεται από τον Κάτοχο Άδειας Κυκλοφορίας.

ΒΙΒΛΙΟΓΡΑΦΙΑ

1. CAMZYOS, Περίληψη Χαρακτηριστικών του Προϊόντος, Μάιος 2025. 2. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759-769.

ΠΡΟΦΙΛ ΑΣΦΑΛΕΙΑΣ

Οι πιο συχνά αναφερόμενες ανεπιθύμητες ενέργειες του CAMZYOS® ήταν ζάλη (17%), δύσπνοια (12%), συστολική δυσλειτουργία (5%) και συγκοπή (5%)¹

ΕΛΛΑΔΑ

Λιανική τιμή (συμπ. 6% ΦΠΑ)*

CAMZYOS CAPS 2.5mg, 5mg, 10mg, 15mg, CAP BTX28 (2X14) CAPS ΣΕ BLISTER (PVC/PCTFE/ALU): €1.443,68

*Σύμφωνα με το Δελτίο αναθεωρημένων τιμών φαρμάκων ανθρώπινης χρήσης, Δεκεμβρίου 2025

ΚΥΠΡΟΣ

Μέγιστη Δυνατή Λιανική Τιμή με ΦΠΑ*

CAMZYOS CAPSULE, HARD 2.5mg, 5mg, 10mg, 15mg, PACK WITH 28 CAPS IN BLISTER(S): €1.602,21

*Σύμφωνα με το Δελτίο αναθεωρημένων τιμών φαρμάκων ανθρώπινης χρήσης, Φεβρουαρίου 2026

ΤΡΟΠΟΣ ΔΙΑΘΕΣΗΣ

Ελλάδα: Με περιορισμένη ιατρική συνταγή από ειδικό ιατρό και παρακολούθηση κατά την διάρκεια της αγωγής
Κύπρος: Με ιατρική συνταγή

Αναφορά πιθανολογούμενων ανεπιθύμητων ενεργειών:

Ελλάδα: Εθνικός Οργανισμός Φαρμάκων,
Μεσογείων 284, GR-15562 Χολαργός, Αθήνα,
Τηλ: + 30 21 32040337

Ιστότοπος: <http://www.eof.gr>, <http://www.kitrinikarta.gr>

Κύπρος: Φαρμακευτικές Υπηρεσίες, Υπουργείο Υγείας,
CY-1475 Λευκωσία, Τηλ: +357 22608607,

Φαξ: + 357 22608669 Ιστότοπος: www.moh.gov.cy/phs

Αρ. άδειας: 76003/04-10-2023

 **Bristol Myers Squibb®**

Bristol-Myers Squibb A.E.

Αττικής 49-53 & Προποντίδος 2,

Τ.Κ. 152 35 Βριλήσσια, Αττική

Τ.Θ. 63883 - Βριλήσσια, Τ.Κ. 152 03, Αττική

Τηλ. 210 6074300 & 210 6074400

Φαξ 210 6074333

Αριθμός Γ.Ε.ΜΗ 7453601000

Πριν τη συνταγογράφηση, συμβουλευτείτε την ισχύουσα Περίληψη Χαρακτηριστικών Προϊόντος που διατίθεται σε έντυπη μορφή από τον Κάτοχο Άδειας Κυκλοφορίας ή μέσω σάρωσης του παρακάτω QR code.



Ημερομηνία Αναθεώρησης Κειμένου: 05/2025

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»
www.kitrinikarta.gr
www.kitrinikarta.gov.cy

▼Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει το γρήγορο προσδιορισμό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιοδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες. Βλ. παράγραφο 4.8 για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.

PHILIPS | TOMTEC AI

www.philips.com





Ziviba®

Ezetimibe & Rosuvastatin

Xavertia®

Rivaroxaban



Zonylia®

Ezetimibe & Atorvastatin

Τρόπος διάθεσης: Με Ιατρική συνταγή
Λιανική τιμή Δ.Τ. 05.2025

ZONYLIA® F.C.TAB (10+10)MG/TAB BT X 30 TABS 23,92€
ZONYLIA® F.C.TAB (10+20)MG/TAB BT X 30 TABS 24,94€
ZONYLIA® F.C.TAB (10+40)MG/TAB BT X 30 TABS 26,97€

ZIVIBA® F.C.TAB (5+10)MG/TAB BT X 30 F.C.TAB 23,26€
ZIVIBA® F.C.TAB (10+10)MG/TAB BT X 30 F.C.TAB 23,62€
ZIVIBA® F.C.TAB (20+10)MG/TAB BT X 30 F.C.TAB 27,70€
ZIVIBA® F.C.TAB (40+10)MG/TAB BT X 30 F.C.TAB 31,05€

XAVERTIA® F.C.TAB 10MG/TAB BT x 30 TABS 46,11 €
XAVERTIA® F.C.TAB 15MG/TAB BT x 30 TABS 44,64 €
XAVERTIA® F.C.TAB 20MG/TAB BT x 30 TABS 44,64 €

ZbZnXv-Adv02-0725

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή
και Αναφέρετε

ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «**Κίτρινη Κάρτα**»

Πριν τη συνταγογράφηση συμβουλευτείτε τις ΠΧΠ των
προϊόντων οι οποίες υπάρχουν διαθέσιμες από την
εταιρεία, εφόσον ζητηθούν

Σε περίπτωση τροποποίησης του ΔΤ ισχύει η νεότερη
τιμή, συμπεριλαμβανομένου ΦΠΑ όπως ισχύει.


innovis
Future health today

INNOVIS PHARMA A.E.B.E.
Λεωφ. Κηφισίας 44
Μαρούσι, 15125
Τ: +30 2162005600
F: +30 2106664804
www.innovispharma.gr

Presented at EuroPCR 2025

LANDMARK

Randomised Controlled Trial

768
PATIENTS

31
CLINICAL SITES

16
COUNTRIES

1 year results

Myval THV series at **one year** was **non-inferior** to the contemporary THVs (Sapien and Evolut THV series) with respect to the clinical efficacy endpoint.

13.0 %

**Myval
THV series**

vs.

13.1 %

**Sapien and Evolut
THV series**

(Difference: -0.1%, one-sided 95% CI: 3.9%, $P_{\text{non-inferiority}} < 0.0001$)

Key findings

For the treatment of patients with symptomatic severe native aortic stenosis, the **Myval THV series** at **one year** was **non-inferior** to the contemporary THVs (Sapien and Evolut) with respect to the clinical efficacy endpoint.
(Difference: -0.1%, one-sided 95% CI: 3.9%, $P_{\text{non-inferiority}} < 0.0001$).

LANDMARK is the the **first randomized TAVI head-to-head trial** to report the **VARC-3** recommended composite endpoint of clinical efficacy combined with QOL at one year.
(19.5% vs. 22.7%, difference: -3.2%, 95% CI: -9.2 to 2.9, $P = 0.33$).

The hemodynamic results (93% echo assessment) provide robust conclusions on the **stable hemodynamic performance** of the two arms over a year.
(EOA, mean PG and presence of \geq moderate aortic regurgitation were comparable).


Myval THV series demonstrates comparable survival (92.8% vs. 92.9%) to contemporary THV series, underscoring its overall safety.

As presented by Prof. Serruys at the Hotline TAVI 1 session, EuroPCR 2025

 **Vyndaqel**[®]
(*tafamidis*)



Μάθετε περισσότερα στο
www.pfizerpro.gr/medicine/vyndaqel



Πριν τη συνταγογράφηση συμβουλευτείτε την Περίληψη Χαρακτηριστικών του Προϊόντος που διατίθεται από την εταιρεία.

▼ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει το γρήγορο προσδιορισμό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιοσδήποτε πιθανολογούμενες ανεπιθύμητες ενέργειες. Βλ. παράγραφο 4.8 της Περίληψης Χαρακτηριστικών του Προϊόντος για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για
ΟΛΑ τα φάρμακα
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»




OPTISON™

HUMAN ALBUMIN MICROSPHERES CONTAINING PERFLUTREN

For difficult-to-image patients, a simple-to-use solution

Λ.Τ: 83,99 €

ΕΤΟΙΜΟ ΓΙΑ ΕΓΧΥΣΗ



Οι τιμές ακολουθούν το εκάστοτε Δελτίο Τιμών που εκδίδει το αρμόδιο υπουργείο.

Σε περίπτωση δημοσίευσης νέου Δελτίου Τιμών, θα ισχύει το νεότερο.

Τρόπος διάθεσης με ιατρική συνταγή

Πριν τη συνταγογράφηση συμβουλευτείται την ΠΧΠ, η οποία είναι διαθέσιμη από την εταιρεία εφόσον ζητηθεί.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε: ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»

Πρωθυούμενο από την

PharmaZac

Pharmazac S.A.
pharmazac@pharmazac.com

Αναστάσιου Ζαρολιάγκη 1 & Δημήτριου Λάμπρου 6,
ΒΙΟ.ΠΑ. Κερατέας, 190 01 Κερατέα

T: 210 341 8889 - 95

www.pharmazac.com

Αριθμός ΓΕΜΗ 1820201000

K.A.K



GE HealthCare

Σωρού 8 - 10, 15125
Μαρούσι, Αθήνα
T: (+30) 210 89 30 600

www.gehealthcare.gr

Curilen®

Bisoprolol fumarate + Acetylsalicylic acid

Βισοπρολόλη
5 mg / 10 mg

Ακετυλοσαλικυλικό οξύ
100 mg



Πριν τη συνταγογράφηση,
συμβουλευτείτε την ΠΧΠ
σαρώνοντας τον κωδικό QR.



Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και
Αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα.
Συμμελώνοντας στην "ΚΙΤΡΙΝΗ ΚΑΡΤΑ".

Curilen 5 mg/100 mg, ΑΤ: 8,16 €
Curilen 10 mg/100 mg, ΑΤ: 8,30 €



Pharmaceutical Laboratories S.A.



ΓΙΑ 3^η ΣΥΝΕΧΟΜΕΝΗ ΧΡΟΝΙΑ



61 χρόνια UNI-PHARMA.
Αξία για τον άνθρωπο.
Ευθύνη για την κοινωνία.

14^ο χλμ. Εθνικής Οδού 1, 145 64 Κηφισιά
Τηλ.: 210-80 72 512, Fax: 210-80 78 907
e-mail: unipharma@uni-pharma.gr

www.uni-pharma.gr



LIFE FROM INSIDE

The contrast imaging specialists



iomeron[®]

Iomeprol

400

High concentration

Higher signal in first-pass CT



Reduced

- contrast volume and flow rate
- radiation dose in CTA
- risk of CIN



ProHance[®]

gadoteridol

Trust the Pro



Proudly macrocyclic



Proudly different



Proudly rapid



Proudly effective



Proudly well tolerated


Not only promises

Proofs



sulphur hexafluoride

Experience Real Time Diagnosis



CEUS in

- Liver Imaging
- Vascular Imaging
- Cardiac Imaging

& for detection of vesicoureteral reflux



LIFE FROM INSIDE

Committed to Science,
Committed to You.™



Λ. Πηγής 33 & Αναπήρων Πολέμου 6, 151 27 Μελίσσια, Αθήνα
T. 210 6199886 - www.leriva.com